{"id":616887,"date":"2022-09-16T22:30:01","date_gmt":"2022-09-16T22:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616887"},"modified":"2022-09-16T22:30:01","modified_gmt":"2022-09-16T22:30:01","slug":"hepatorenal-syndrome-market-is-projected-to-grow-during-the-forecast-period-2032-delveinsight-key-players-mallinckrodt-terlivazterlipressin-ocelot-bio-oce205-biovie-noorik","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatorenal-syndrome-market-is-projected-to-grow-during-the-forecast-period-2032-delveinsight-key-players-mallinckrodt-terlivazterlipressin-ocelot-bio-oce205-biovie-noorik_616887.html","title":{"rendered":"Hepatorenal Syndrome Market is Projected to Grow During the Forecast Period (2032) – DelveInsight | Key Players – Mallinckrodt (Terlivaz\/terlipressin), Ocelot Bio (OCE-205), BioVie, Noorik,"},"content":{"rendered":"
\n
\"Hepatorenal<\/a><\/div>\n
\n
Delveinsight Business Research LLP\n<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, globally, nearly 3+ key pharma and biotech companies are working on 3+ pipeline drugs in the Hepatorenal Syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. The launch of emerging therapies is expected to transform the Hepatorenal Syndrome treatment outlook in the coming years.<\/div>\n

DelveInsight’s “Hepatorenal Syndrome Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hepatorenal Syndrome Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Hepatorenal Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Hepatorenal<\/p>\n

Hepatorenal Syndrome: An Overview<\/strong><\/p>\n

Hepatorenal syndrome is a serious complication of liver cirrhosis with a critically poor prognosis. The pathophysiological hallmark is severe renal vasoconstriction, resulting from complex changes in splanchnic and general circulations and systemic and renal vasoconstrictors and vasodilators.<\/p>\n

Hepatorenal Syndrome always develops in the setting of advanced circulatory dysfunction, and it is always accompanied by ascites and usually hyponatremia.<\/em> <\/p>\n

Hepatorenal Syndrome Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hepatorenal Syndrome market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.<\/p>\n

The report details the Hepatorenal Syndrome market trend<\/strong> for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n

Hepatorenal Syndrome Epidemiology<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n

Hepatorenal Syndrome Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatorenal Syndrome market<\/strong> or expected to get launched during the study period. The analysis covers Hepatorenal Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Hepatorenal Syndrome Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Key Developments in the Hepatorenal Syndrome Therapeutics Market<\/strong><\/p>\n

On Sep 14, 2022, Mallinckrodt plc (OTCMKTS: MNKPF)<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> approved Terlivaz® (terlipressin)<\/strong> for injection. The approval makes Terlivaz, the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with a rapid reduction in kidney function.<\/em><\/p>\n

On August 22, 2022, Ocelot Bio<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> has granted Orphan Drug Designation<\/strong> to its lead candidate OCE-205<\/strong> for the treatment of hepatorenal syndrome. OCE-205<\/strong> is a mixed agonist-antagonist peptide therapeutic designed to selectively target the vasopressin 1a (V1a) receptor.<\/em><\/p>\n

Learn how the Hepatorenal Syndrome Market will evolve in the coming years at:
<\/strong>https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/strong><\/a><\/p>\n

Hepatorenal Syndrome Therapeutics Analysis<\/strong><\/p>\n

There are approx. 3+ key companies<\/strong> which are developing therapies for Hepatorenal Syndrome. Currently, Noorik Biopharmaceuticals<\/strong> has its Hepatorenal Syndrome drug candidates in the most advanced stage of clinical development.<\/em><\/p>\n

Some of the key companies in the Hepatorenal Syndrome Therapeutic Market include:<\/strong><\/p>\n

• Noorik Biopharmaceuticals<\/p>\n

• Cumberland Pharmaceuticals<\/p>\n

• BioVie<\/p>\n

And many others<\/strong><\/p>\n

Hepatorenal Syndrome Emerging Drugs<\/strong><\/p>\n

• Ambrisentan: Noorik Biopharmaceuticals<\/p>\n

• Ifetroban: Cumberland Pharmaceuticals<\/p>\n

And many more<\/strong><\/p>\n

Further product details are provided in the report. Download the sample Report to get more detailed insights at:<\/strong>
https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/strong><\/a><\/p>\n

Table of Content (TOC)<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary <\/p>\n

3. Hepatorenal Syndrome Competitive Intelligence Analysis<\/p>\n

4. Hepatorenal Syndrome Market Overview at a Glance<\/p>\n

5. Hepatorenal Syndrome Disease Background and Overview<\/p>\n

6. Hepatorenal Syndrome Patient Journey<\/p>\n

7. Hepatorenal Syndrome Epidemiology and Patient Population<\/p>\n

8. Hepatorenal Syndrome Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Hepatorenal Syndrome Unmet Needs<\/p>\n

10. Key Endpoints of Hepatorenal Syndrome Treatment<\/p>\n

11. Hepatorenal Syndrome Marketed Products<\/p>\n

12. Hepatorenal Syndrome Emerging Therapies<\/p>\n

13. Hepatorenal Syndrome Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Hepatorenal Syndrome Market Outlook (7 major markets)<\/p>\n

16. Hepatorenal Syndrome Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Hepatorenal Syndrome Market.<\/p>\n

18. Hepatorenal Syndrome Market Drivers<\/p>\n

19. Hepatorenal Syndrome Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n

Download Sample PDF Report – https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/p>\n

<\/a><\/strong><\/p>\n

About DelveInsight
<\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n

Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n

Global Kinase Inhibitor in Autoimmune Diseases Market
<\/a><\/strong>“Global Kinase Inhibitor in Autoimmune Diseases Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Kinase Inhibitor in Autoimmune Diseases Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Shruti Thakur
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, nearly 3+ key pharma and biotech companies are working on 3+ pipeline drugs in the Hepatorenal Syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,425,426,417,404],"tags":[],"class_list":["post-616887","post","type-post","status-publish","format-standard","hentry","category-Business","category-Finance","category-Financial-Market","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616887"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616887\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}